The Clinical journal of pain
-
Activity pacing is a common intervention for patients with chronic pain. Over the past decade a number of instruments have been developed to measure this construct, but their comparative psychometric properties have not been examined. ⋯ Current measures of activity pacing are inadequate. New measures are needed that are based on specific theoretical models; these measures should also make the goal or intent of pacing behaviors explicit. Improvements in the assessment of activity pacing will likely lead to a better understanding of the pacing construct and the effects of pacing interventions.
-
Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain. In recent years, GBP has been used as an adjunct or primary therapy in non-neuropathic pain, most commonly for the treatment of perioperative and cancer pain. ⋯ Although efficacy varies, multiple well-designed clinical trials have demonstrated reduced pain and analgesic use with otolaryngology, orthopedic, mastectomy, and abdominal/pelvic surgical perioperative use of GBP, whereas there is limited or no efficacy for cardiothoracic surgery. Cancer pain studies have had greater design variability, often nonblinded, with pain benefit being mild to moderate, and more efficacious with partial neuropathic pain quality. Overall, GBP seems to have significant benefit in neuropathic and non-neuropathic pain associated with the perioperative period and cancer. Considering its favorable side effect profile, GBP represents a beneficial pain adjunctive therapy, beyond neuropathic symptoms.